Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doxazosin Mesylate

FDA-approved product (tablet, oral), marketed as Cardura, Cardura Xl, Doxazosin Mesylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Doxazosin Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Hypertension
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Doxazosin Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxazosin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy

    NCT00295542 · start 2000-03

    Registered record
    Registry ID
    NCT00295542
    Conditions
    Hypertension
    Interventions
    Ambulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan); beta blockers (including nebivolol, atenolol, carvedilol); diuretics (torasemide, indapamide, HTCZ) and doxazosin; Combination therapy in essential hypertension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-03
    Completion
    2009-04
    Enrolment
    3,344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmbulatory blood pressure monitoring; Chronotherapy, timing of antihypertensive medication; ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) +3 more
    PhasePhase 4
    Registry statusCompleted

  • Medical Therapy of Prostatic Symptoms

    NCT00021814 · start 1995-12

    Registered record
    Registry ID
    NCT00021814
    Conditions
    Prostatic Hyperplasia; Prostatic Hypertrophy, Benign
    Interventions
    Doxazosin; Finasteride; Doxazosin placebo; Finasteride placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-12
    Completion
    2001-11-30
    Enrolment
    3,407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia; Prostatic Hypertrophy, Benign
    InterventionDoxazosin; Finasteride; Doxazosin placebo; Finasteride placebo
    PhasePhase 3
    Registry statusCompleted

  • Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

    NCT00000542 · start 1993-08

    Registered record
    Registry ID
    NCT00000542
    Conditions
    Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Heart Diseases; Hypercholesterolemia; Hypertension; Myocardial Infarction; Myocardial Ischemia; Heart Failure
    Interventions
    Inhibitors, ACE; amlodipine; lisinopril; doxazosin; chlorthalidone; pravastatin; diet, fat-restricted
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1993-08
    Completion
    2002-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Heart Diseases +5 more
    InterventionInhibitors, ACE; amlodipine; lisinopril; doxazosin +3 more
    PhasePhase 3
    Registry statusCompleted

  • Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

    NCT00004266 · start 1993-08

    Registered record
    Registry ID
    NCT00004266
    Conditions
    Diabetic Nephropathy
    Interventions
    Lisinopril; Nifedipine; Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1993-08
    Completion
    1999-07
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy
    InterventionLisinopril; Nifedipine; Simvastatin
    PhasePhase 3
    Registry statusCompleted

  • Treatment of Mild Hypertension Study (TOMHS)

    NCT00000522 · start 1985-08

    Registered record
    Registry ID
    NCT00000522
    Conditions
    Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventions
    diet, sodium-restricted; diet, reducing; exercise; alcohol restriction; chlorthalidone; acebutolol; doxazosin; amlodipine; enalapril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1985-08
    Completion
    1994-05
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
    Interventiondiet, sodium-restricted; diet, reducing; exercise; alcohol restriction +5 more
    PhasePhase 2
    Registry statusCompleted